Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System

Clinical Drug Investigation 2026

View at publisher

Authors: Solomiya Gumenyuk, Ajay Ogirala, Steven T. Szabo, Kenneth S. Koblan, Seth C. Hopkins, Mike Ufer

DOI: 10.1007/s40261-026-01525-3

Cited by: 0

References: 34

Fields of Study & Subjects

Pharmacovigilance and Adverse Drug Reactions Schizophrenia research and treatment Attention Deficit Hyperactivity Disorder

References 34